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Abstract The ability of five members of the cytokine-inducible
SH2 protein family (CIS1^4) and JAK2 binding (JAB) protein
to affect prolactin receptor (PRLR)-mediated activity was tested
in human 293 embryonic kidney fibroblasts transiently trans-
fected with rat PRLR, five concentrations of CIS/JAB Myc-
tagged cDNAs and a STAT5-responsive reporter gene encoding
luciferase. The protein expressions of CIS1, CIS2, CIS3 and
JAB were comparable, whereas the level of CIS4 was slightly
lower. PRLR-mediated luciferase activity was abolished in a
dose-dependent manner in cells transfected with cDNA of CIS3
or JAB, even at concentrations below the level of protein
detection by anti-Myc antibody. In contrast, CIS1, CIS2 and
CIS4 had little or no effect, despite similar levels of expression.
CIS1 expression in postpartum mouse mammary glands was high
and changed little in the course of 3 days. CIS2 and CIS3
expression was also high and increased further, whereas JAB
expression was very low. These results hint that at least in
mammary gland CIS3 is likely the main physiological negative
regulator of the PRLR-mediated JAK2/STAT5 pathway.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Prolactin receptors (PRLRs) belong to the cytokine recep-
tor family, which consists of transmembrane single-chain pro-
teins with considerable similarity in their extracellular do-
mains, also termed cytokine homology domains [1,2]. The
mechanism of prolactin (PRL) signaling has been intensively
investigated over the last decade, leading to a well-established
paradigm, namely: the signal is initiated by hormone-induced
receptor homodimerization, which leads to immediate trans-
phosphorylation of the associated tyrosine kinase JAK2, fol-
lowed by activation of STAT5 or MAP kinase pathways [3^5].
Although this paradigm is in general correct for other cyto-
kines, we have recently documented that unlike growth hor-
mones (GHs), the interaction of PRLs with their homologous
receptors is extremely transient, albeit su⁄cient to activate the
signal transduction [6]. One possible reason for this could be
related to the ¢nding that JAK2 kinase, which serves as a ¢rst
mediator of both receptors, is already associated with lacto-
genic receptors prior to hormone-binding-induced receptor
dimerization [7,8]. We suggested that once the signal is initi-
ated, the homodimer is no longer required and the activated
tyrosine-phosphorylated JAK2 continues its enzymatic activ-
ity and is capable of docking and/or phosphorylating down-
stream proteins [9,10]. Little is known, however, about how
this signal pathway is terminated or attenuated. In the case of
erythropoietin (EPO) receptor the phosphorylated intracellu-
lar domain of the receptor is capable of binding the protein
tyrosine phosphatase SHP-1, which in turn dephosphorylates
the activated JAK2 [11]. Whether this or a similar mechanism
also exists in other members of the cytokine family, or
whether the signal is only attenuated by receptor internaliza-
tion, is not clear. Indirect evidence hints at the involvement of
tyrosine phosphatase in PRLR-mediated pathways [12,13],
although con£icting results suggest that the protein tyrosine
phosphatase SHP-2 acts as a positive rather than negative
regulator [14]. In the last three years, a new family of proteins
termed cytokine-inducible SH2-containing proteins (CIS)
[15,16], JAK2 binding protein (JAB) [17], suppressors of cy-
tokine signaling (SOCS) [18] or STAT-induced STAT inhib-
itors (SSI) [19], which are involved in attenuating cytokine
signaling, has been cloned and partially characterized. At
present, this family consists of seven (CIS1^6 and JAB) [16]
or eight members, though it may be larger [20]. The inhibitory
activity of these proteins results from their ability to interact
with JAK family members, with tyrosine-phosphorylated
STATs or with cytokine receptors [15^21]. Whether this inter-
action leads to dephosphorylation of these proteins via the
recruitment of phosphatases, or by blocking phosphotyrosine
docking sites, and what their speci¢city is toward di¡erent
cytokines, is only partially understood. Involvement of these
proteins in PRLR-mediated signaling has not yet been re-
ported, though it has been suggested that some of them are
likely to be involved in its regulation [5]. In order to extend
this knowledge, we tested the ability of ¢ve members of the
CIS/JAB family to a¡ect PRLR-mediated STAT5-dependent
activity, using human 293 embryonic kidney (HEK) ¢broblast
cells transiently transfected with rat (r) PRLR and a reporter
gene as a model [22,23]. In parallel, we checked the expression
of CIS/JAB in postpartum mouse mammary glands.
2. Materials and methods
2.1. Materials
Recombinant bovine placental lactogen (bPL) was prepared as de-
scribed previously [24]. Molecular mass markers for SDS-PAGE,
DMEM and DMEM/F12 media were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). Horseradish peroxidase (HRP)-conjugated
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antibodies for Western blot analysis were purchased from Enco Co.
(Jerusalem, Israel), SDS-PAGE reagents from Bio-Rad Laboratories
(Richmond, CA, USA), enhanced chemiluminescence (ECL) reagents
for Western blot analysis from Amersham (Buckinghamshire, UK),
fetal calf serum (FCS) from Bet Haemek Co. (Jerusalem, Israel) and
luciferin from Promega Inc. (Madison, WI, USA). Vectors encoding
the full-size rPRLR in pRc/CMV and luciferase were obtained from
Drs. P.A. Kelly and V. Go⁄n [22], and preparation of Myc-tagged
(repeated ¢ve times) CIS was as previously reported [16]. All other
chemicals were of analytical grade.
2.2. In vitro bioassays in transiently transfected 293 HEK cells
The e¡ect of ¢ve CIS/JAB-encoding constructs on lactogen-induci-
ble activity was assayed in 293 cells transiently co-transfected with
vectors encoding rPRLR and the luciferase reporter gene; the latter
is controlled by a six-repeat sequence of LHRE (lactogenic hormone
response element with a STAT5 binding sequence) fused to a minimal
TK promoter. The transfection and bioassay were carried out as de-
scribed previously [22,23]. The experiments were performed in six-well
plates. Each pair of wells was co-transfected with identical amounts of
rPRLR and LHRE-luciferase (0.1 Wg DNA) and di¡erent concentra-
tions of CIS1^4 or JAB (for the speci¢c concentrations see the legend
to Fig. 1) using the calcium-phosphate method. The initial concentra-
tions of CIS1^4 and JAB DNAs were chosen to achieve similar levels
of expression [16]. After 24 h, one of the two wells was activated by
adding 400 ng bPL. After a further 24 h, the cells from each well were
lysed in 0.5 ml lysis bu¡er and luciferase activity was determined in a
50 Wl aliquot using a Biocounter M 2500 apparatus (Lumac, Celsis,
The Netherlands). The protein concentration in each lysate was de-
termined with Bradford reagent (Bio-Rad Laboratories Ltd, Hemel
Hempstead, UK). The protein concentrations were in general close to
1 Wg/Wl (the maximal range was 0.6^1.3 Wg/Wl) and the activity was
normalized per 50 Wg protein. Then the relative lactogen-induced lu-
ciferase activity for each well pair was calculated as follows: (activity
in the well activated with bPL)/(activity in the non-activated well).
The six values obtained from two plates transfected with each of
the CIS or JAB constructs were normalized using the following equa-
tion: (activity in cells transfected with CIS or JAB31)/(activity in
non-transfected cells31)U100. The ¢nal results are presented as the
mean þ S.E.M. of four experiments.
2.3. Expression of CIS/JAB in postpartum mammary glands
Two mice were killed at days 1, 2 and 3 postpartum and total RNA
was prepared. For Northern blotting, 5 Wg of total RNA of mouse
mammary gland at 1, 2 and 3 days postpartum was separated on 1.0%
agarose gels containing 2.4% formaldehyde, then transferred to pos-
itively charged nylon membranes. Preparation of RNA, probe cDNAs
and hybridization were as described previously [16] and K-lactalbumin
was used as a control [25]. The density of the band was determined
with a UMAX scanner, using the NIH program for MacIntosh com-
puter.
3. Results and discussion
Our previous results indicated that the e⁄ciency of trans-
fection with rPRLR and reporter gene constructs shows little
variation [23]. Therefore, instead of assaying the e⁄ciency of
transfection by an unrelated vector, we detected it directly by
measuring the expression of the transfected CIS/JAB con-
structs, using Western blotting with anti-Myc antibodies. As
shown in Fig. 1 (lane 5) the expressions of CIS1, CIS2, CIS3
and JAB proteins in cells transfected with 10, 10, 5 and 0.5 Wg
of cDNA, respectively, were comparable, whereas the level of
CIS4 in cells transfected with 5 Wg was slightly lower. The
proteins were clearly detected in cells transfected with the
highest cDNA concentration (lane 5) or with the ¢rst 1:8
cDNA dilution (lane 4), but were barely visible or below the
level of detection at lower DNA concentrations (lanes 1^3).
To assay the e¡ect of CIS/JAB on PRLR-mediated signal-
ing, we chose bPL, which activates all PRLRs [24,26]. The
concentration of bPL was chosen to achieve a sub-maximal
response, as determined by preliminary experiments (not
shown). The results shown in Fig. 2 clearly indicate that
bPL-inducible luciferase activity is abolished in a dose-de-
pendent manner in 293 cells transiently transfected with
cDNAs of CIS3 or JAB. Partial inhibition was already ob-
served in cells transfected with as little as 1.2 ng of CIS3 or
0.12 ng of JAB constructs (bar 1) (13% and 35% respectively,
only the latter di¡erence being statistically signi¢cant,
P6 0.05). At eightfold higher construct concentrations (9.6
ng of CIS3 or 0.96 ng of JAB) 50% and 70% of inhibition
was observed (bar 2) and the respective di¡erences were stat-
istically signi¢cant (P6 0.05 and P6 0.01). At still higher
cDNA concentrations, the inhibition was complete (bars
4 and 5) or nearly so (bar 3). It seems, therefore, that bPL-
inducible activity can be attenuated by very low concentra-
tions of both CIS3 and JAB proteins, i.e. those below the level
of anti-Myc antibody detection. Our results are similar to
those reported by others, in cells transfected with receptors
of EPO or leukemia inhibitory factor (LIF) [16,27], interleu-
kin-6 (IL6) [18], GH [28], interferon-Q [29], and in cells ex-
pressing an intact long form of leptin receptors [30], thus
indicating that CIS3 and JAB are major negative regulators
in cytokine signaling.
In contrast to our ¢ndings with CIS3 and JAB, transfection
of 293 cells with CIS1, CIS2 and CIS4 cDNA had little or no
e¡ect on bPL-inducible activity (Fig. 2), although their levels
of expression (see above) were similar to those of CIS3 and
JAB. Some statistically signi¢cant decrease (P6 0.05) was ob-
served, in cells transfected with 10 Wg CIS2 or 5 Wg of CIS4
(bar 5). Thus, it seems that the inhibition of lactogen-induci-
ble signal transduction is at least 500^4000 times less sensitive
to CIS2 and CIS4 than to CIS3 and JAB, suggesting that the
former proteins do not interfere with PRLR-mediated STAT5
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Fig. 1. Expression of CIS1^4 and JAB in cells co-transfected with
constructs of rPRLR (0.1 Wg), LHRE-luciferase (0.1 Wg) and various
concentrations of CIS1^4 and JAB. The concentrations of the trans-
fected DNAs of the latter were: CTRL: none; lanes 5^1: consecu-
tive eightfold dilutions from the highest to the lowest concentra-
tions. The highest concentrations of the respective DNAs per well
(lane 5) were: CIS1 10 Wg, CIS2 10 Wg, CIS3 5 Wg, CIS4 5 Wg, JAB
0.5 Wg. The cell lysates (30 Wl) were fractionated by 10% SDS-
PAGE in minigels, blotted and developed with anti-Myc serum. For
more details see text.
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signaling. Interestingly, in cells transfected with lower concen-
trations of CIS4, bPL-inducible activity was elevated by 60^
70% (Fig. 2, bars 3 and 4). Though one of these increases was
signi¢cantly di¡erent from the control the nature of this in-
crease is not clear. It should also be noted that the transfected
CIS/JAB constructs did not a¡ect the basal luciferase activity
in cells that were not stimulated with bPL, except in cells
transfected with the highest concentration of JAB (0.5 Wg),
in which the basal activity was elevated two- to threefold
(not shown).
Previous studies have shown that both CIS3 and JAB have
the in vitro and in vivo capacity to interact with the JAK2-
JH1 domain, with JAB’s interaction being considerably stron-
ger [16]. However, the present results indicate that the inhi-
bition pattern of PRLR-mediated luciferase activity is almost
identical for both CIS3 and JAB (see Figs. 1 and 2). One
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Fig. 3. Northern analysis of CIS1^3 expression in postpartum mouse mammary gland. Total RNA prepared from 1, 2 and 3 days postpartum
mammary gland (5 Wg) was analyzed. Probing of K-lactalbumin was used as a control.
Fig. 2. E¡ect of CIS1^4 and JAB on bPL-inducible luciferase activity in 293 cells that were co-transfected with constructs of rPRLR (0.1 Wg),
LHRE-luciferase (0.1 Wg) and various concentrations of CIS1^4 and JAB. For the concentrations of the transfected constructs see the legend to
Fig. 1. Each of the wells in a six-well plate was transfected with identical amounts of rPRLR and LHRE-luciferase and di¡erent concentrations
of CIS1^4 or JAB. One of the two wells was activated by bPL as described in Section 2. After the results were normalized to the same protein
level in lysates the relative lactogen-induced luciferase activity for each couple of wells was calculated as follows: (activity in the well activated
with bPL)/(activity in the non-activated well) and the values obtained from each pair of wells were normalized using the following equation:
(activity in cells transfected with CIS or JAB31)/(activity in non-transfected cells31)U100. The ¢nal results are presented as the mean þ S.E.M.
of the four experiments. Results signi¢cantly di¡erent from the control (as analyzed by two-way t-test) are marked with * (P6 0.05) or
** (P6 0.01).
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possible explanation for this discrepancy is that CIS3 may
have additional inhibitory functions unrelated to JAK2 bind-
ing, the nature of which is at present unknown. Indeed,
whereas the only function related to JAB activity to date is
its interaction with either JAK2 [21], or other related kinases,
such as JAK1, JAK3 and Tyk [17], and with a non-receptor
Tec protein-tyrosine kinase [31], CIS3 has been shown to in-
teract with lck [16]. Though participation of lck in PRLR
signaling has not been reported [5], another src-like kinase,
Fyn, was activated by PRLR stimulation in a Nb2 rat T-
lymphoma cell line [32] and an association of PRLR with c-
srk kinase in rat liver has also been suggested [33]. Therefore,
the inhibitory e¡ect of CIS3 in PRLR-transfected 293 cells
may not be limited to an interaction with JAK2. Since trans-
activation of luciferase is controlled by LHRE promoter,
which also requires phosphorylation of tyrosines 473, 479
and, in particular, 580 in long PRLRs [34], we should consider
them as possible target sites for CIS3. CIS1 has been shown to
interact with the phosphorylated erythropoietin receptor
(EPOR) [16] or interleukin-3RL [35], and CIS1 and CIS2
with insulin-like growth factor-I receptor [36]. The lack of
direct evidence for the e¡ects of CIS1, CIS2 and CIS4 does
not, therefore, preclude their participation in downregulation
of PRL signaling. In fact indirect evidence, namely the hor-
mone-dependent expression of various members of this family
[15^19,27^31], hints at their playing a regulatory role. For
instance, the results shown for a GHR which is closely related
to PRLR indicate GH-dependent upregulation in expression
not only of CIS3 and JAB, but also of CIS1 and CIS2, though
the kinetics and speci¢city di¡er in various tissues or cell lines
bearing GHRs [28].
To assess the physiological relevance of our results, we
tested the expression of CIS/JAB in postpartum lactating
mouse mammary glands. The results shown in Fig. 3 show
results obtained from three randomly chosen mice. The ¢gure
is a representative of two gels that showed similar results. The
relative densities of each band were related to that of K-lact-
albumin at the same day. As shown in Fig. 3, CIS1 is highly
expressed on day 1 postpartum, and the level remains high on
days 2 and 3 (relative densities 1.13, 1.09, 1.14). CIS1 has been
shown to be a target of STAT5 [35], but CIS1 expression was
undetectable in STAT5A,B double-knockout mice [37]. There-
fore, CIS1 may serve as a target gene of PRL signaling. How-
ever, overexpression of CIS1 did not inhibit PRL-dependent
STAT5 activation in 293 cells (Fig. 2), while it partially in-
hibited EPO-dependent STAT5 activation [16]. Furthermore
we did not obtain any direct evidence indicating the interac-
tion between the PRL receptor and CIS1 (data not shown).
Thus, further study is necessary to clarify the function of CIS1
in mammary gland. In contrast, CIS2 and CIS3 expression
gradually increased in postpartum mammary gland (Fig. 3)
and the following relative densities were obtained for days
1, 2 and 3: CIS2 0.36, 0.67, 0.77 and CIS3 0.52, 0.78, 0.85.
In contrast, JAB expression was below our detection limit
using Northern blots, even after lactation (not shown). As
an increase in circulating prolactin in response to suckling is
well-documented [38], our results (Figs. 2 and 3) hint that
CIS3 may be the physiological inhibitor of the PRLR system
in mammary gland.
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